Johnson & Johnson: Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...
Health and Me on MSN

Blood Sugar Levels In Type 2 Diabetes: What Counts As High, Low, Or Normal?

Type 2 diabetes is a condition where the body struggles to manage blood sugar, and monitoring levels is key to staying ...